Vyne Therapeutics Stock Buy Hold or Sell Recommendation
| VYNE Stock | USD 2.65 0.15 5.36% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Vyne Therapeutics is 'Strong Sell'. Macroaxis provides Vyne Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding VYNE positions.
Check out Vyne Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide. Note, we conduct extensive research on individual companies such as Vyne and provide practical buy, sell, or hold advice based on investors' constraints. Vyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Vyne |
Execute Vyne Therapeutics Buy or Sell Advice
The Vyne recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Vyne Therapeutics. Macroaxis does not own or have any residual interests in Vyne Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Vyne Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Vyne Therapeutics Trading Alerts and Improvement Suggestions
| Vyne Therapeutics generated a negative expected return over the last 90 days | |
| Vyne Therapeutics has high historical volatility and very poor performance | |
| Vyne Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 424 K. Net Loss for the year was (28.45 M) with profit before overhead, payroll, taxes, and interest of 477 K. | |
| Vyne Therapeutics currently holds about 42.81 M in cash with (25.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.74. | |
| Vyne Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 56.0% of the company outstanding shares are owned by institutional investors |
Vyne Therapeutics Returns Distribution Density
The distribution of Vyne Therapeutics' historical returns is an attempt to chart the uncertainty of Vyne Therapeutics' future price movements. The chart of the probability distribution of Vyne Therapeutics daily returns describes the distribution of returns around its average expected value. We use Vyne Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Vyne Therapeutics returns is essential to provide solid investment advice for Vyne Therapeutics.
| Mean Return | -0.03 | Value At Risk | -8.94 | Potential Upside | 8.75 | Standard Deviation | 5.40 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Vyne Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Vyne Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Vyne Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Vyne Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Vyne stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.04 | |
β | Beta against Dow Jones | -0.6 | |
σ | Overall volatility | 5.40 | |
Ir | Information ratio | -0.0088 |
Vyne Therapeutics Volatility Alert
Vyne Therapeutics exhibits very low volatility with skewness of 0.33 and kurtosis of 1.43. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Vyne Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Vyne Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Vyne Therapeutics Fundamentals Vs Peers
Comparing Vyne Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Vyne Therapeutics' direct or indirect competition across all of the common fundamentals between Vyne Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Vyne Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Vyne Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Vyne Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Vyne Therapeutics to competition |
| Fundamentals | Vyne Therapeutics | Peer Average |
| Return On Equity | -0.6 | -0.31 |
| Return On Asset | -0.35 | -0.14 |
| Operating Margin | (52.51) % | (5.51) % |
| Current Valuation | (28.98 M) | 16.62 B |
| Shares Outstanding | 14.75 M | 571.82 M |
| Shares Owned By Insiders | 8.31 % | 10.09 % |
| Shares Owned By Institutions | 56.03 % | 39.21 % |
| Number Of Shares Shorted | 123.2 K | 4.71 M |
| Price To Book | 0.65 X | 9.51 X |
| Price To Sales | 83.78 X | 11.42 X |
| Revenue | 424 K | 9.43 B |
| Gross Profit | 477 K | 27.38 B |
| EBITDA | (29.26 M) | 3.9 B |
| Net Income | (28.45 M) | 570.98 M |
| Cash And Equivalents | 42.81 M | 2.7 B |
| Cash Per Share | 0.74 X | 5.01 X |
| Total Debt | 214 K | 5.32 B |
| Current Ratio | 7.60 X | 2.16 X |
| Book Value Per Share | 6.29 X | 1.93 K |
| Cash Flow From Operations | (25.34 M) | 971.22 M |
| Short Ratio | 1.23 X | 4.00 X |
| Earnings Per Share | 1.72 X | 3.12 X |
| Target Price | 5.58 | |
| Number Of Employees | 10 | 18.84 K |
| Beta | 1.35 | -0.15 |
| Market Capitalization | 44.25 M | 19.03 B |
| Total Asset | 97.69 M | 29.47 B |
| Retained Earnings | (691.34 M) | 9.33 B |
| Working Capital | 88.42 M | 1.48 B |
| Net Asset | 97.69 M |
Note: Acquisition by Harsch Mutya of 62500 shares of Vyne Therapeutics at 2.7 subject to Rule 16b-3 [view details]
Vyne Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Vyne . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Vyne Therapeutics Buy or Sell Advice
When is the right time to buy or sell Vyne Therapeutics? Buying financial instruments such as Vyne Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Vyne Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Diversified Assets Thematic Idea Now
Diversified Assets
Pablicly traded close-end funds and other entities backed by different types of diversified investments. The Diversified Assets theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Diversified Assets Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Vyne Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Vyne Therapeutics is measured differently than its book value, which is the value of Vyne that is recorded on the company's balance sheet. Investors also form their own opinion of Vyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vyne Therapeutics' market value can be influenced by many factors that don't directly affect Vyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.